BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study
Terminated
- Conditions
- Skin Disease, Infectious
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 108
- Registration Number
- NCT02991131
Mirena Extension Trial
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 364
- Registration Number
- NCT02985541
Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan
Phase 1
Completed
- Conditions
- Endometriosis
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT02975440
A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction
Phase 2
Completed
- Conditions
- Myocardial Infarction
- Interventions
- Drug: Fulacimstat (BAY1142524)Drug: Placebo
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2019-09-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 107
- Registration Number
- NCT02976467
Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1481
- Registration Number
- NCT02975453
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: BAY94-9027
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT02971930
- Locations
- 🇺🇸
Cleveland, Cleveland, Ohio, United States
Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in Sweden
Completed
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15953
- Registration Number
- NCT02963675
Human Photoallergy Test (824/2016)
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: BAY987517Other: Untreated skin
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 53
- Registration Number
- NCT02962869
Human Phototoxicity Test (823/2016)
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: BAY987517Other: Untreated Skin
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 38
- Registration Number
- NCT02962856
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2016-11-10
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 99999
- Registration Number
- NCT02960880
© Copyright 2025. All Rights Reserved by MedPath